{"DataElement":{"publicId":"3121734","version":"1","preferredName":"Blood Coagulation Assessment Ind-3b","preferredDefinition":"an indicator that can have a value of yes, no, or not applicable related to assessment of clot formation in blood.","longName":"3121732v1.0:2958018v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3121732","version":"1","preferredName":"Blood Coagulation Assessment","preferredDefinition":"information related to assessment of clot formation in blood.","longName":"3121730v1.0:2233077v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3121730","version":"1","preferredName":"Blood Coagulation","preferredDefinition":"Blood circulating throughout the body.:The process of clot formation. (from On-line Medical Dictionary)","longName":"C12434:C20812","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blood","conceptCode":"C12434","definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Coagulation","conceptCode":"C20812","definition":"The process of clot formation. (from On-line Medical Dictionary)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B6A7F53-484A-0AD5-E040-BB89AD433968","latestVersionIndicator":"Yes","beginDate":"2010-07-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-15","modifiedBy":"ONEDATA","dateModified":"2010-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233077","version":"1","preferredName":"Assessment","preferredDefinition":"The final result of a determination of the value, significance, or extent of.","longName":"C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F90B5E56-BAFE-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-08","modifiedBy":"ONEDATA","dateModified":"2005-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B6A7F53-4858-0AD5-E040-BB89AD433968","latestVersionIndicator":"Yes","beginDate":"2010-07-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506036","version":"1","preferredName":"Yes No Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"YES_NO_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-759A-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75A4-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-7590-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-757C-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ZHANGWE","dateModified":"2019-01-24","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 8/3/2015 Corrections made to VD in order to restore to original format: removed C49486 as rep term and replaced with C49797; restored long name and definition per Dianne Reeves/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104881","version":"1","longName":"GOG-0227G","context":"NRG"},{"publicId":"4104893","version":"1","longName":"GOG-0230D","context":"NRG"},{"publicId":"4104897","version":"1","longName":"GOG-0250","context":"NRG"},{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000693","version":"1","longName":"GOG-9923","context":"NRG"},{"publicId":"4104931","version":"1","longName":"GOG-9923","context":"NRG"},{"publicId":"10000692","version":"1","longName":"GOG-9923","context":"NRG"},{"publicId":"4104938","version":"1","longName":"GOG-0254","context":"NRG"},{"publicId":"4104940","version":"1","longName":"GOG-0268","context":"NRG"},{"publicId":"4104917","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000174","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000175","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"4104892","version":"1","longName":"GOG-0229O","context":"NRG"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"3121732v1.0:2958018v1.0","type":"USED_BY","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Is the PT INR less than or eq","type":"Preferred Question Text","description":"Is the PT INR less than or equal to 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and the PTT less than 1.2 times the Upper Limit of Normal","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Is the PT INR less than or equal to 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thrombo-embolus) and the PTT less than 1.2 times the Upper Limit of Normal?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Is the prothrombin time such that the International Normalized Ratio (INR) is less than or equal to 1.5 X ULN?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Is the PT INR less than or equal to 1.5 x ULN (or an in range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and the PTT less than 1.5 x ULN?","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"PT <= 1.5 x upper limit of normal (ULN)","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Is the Prothrombin Time (PT) such that the International Normalized Ratio (INR) is less than or equal to 1.3 X ULN?","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"If yes, is the patient taking a dose of 2 mg/day or less for prophylaxis of thrombosis?","url":null,"context":"CTEP"},{"name":"CRF Text8","type":"Alternate Question Text","description":"Are the patient's international normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.5 X ULN?","url":null,"context":"CTEP"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Prothrombin time (PT) <=1.5 x institutional normal (ULN)","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"If not on Coumadin, is the patient's international normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.5 x ULN?","url":null,"context":"NRG"},{"name":"Is pre-study INR greater than or equal to 1.5 x upper limit of normal or PT greater than or equal to 1.5x upper limit of normal sec above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosis?","type":"Alternate Question Text","description":"Is pre-study INR greater than or equal to 1.5 x upper limit of normal or PT greater than or equal to 1.5 x upper limit of normal seconds above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosis?","url":null,"context":"Theradex"},{"name":"NRG CRF_Text11","type":"Alternate Question Text","description":"Is the INR or PT less than or equal to 1.5 x ULN (or is PT or INR within therapeutic range of intended use of anticoagulants, if patient is receiving anticoagulant therapy) and the aPTT less than 1.5 x ULN?","url":null,"context":"NRG"},{"name":"CRF_Text_10","type":"Alternate Question Text","description":"Is international normalized ratio (INR) less than or equal to 1.5 x ULN (or an inrange INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a PTT less than or equal to 1.5 x ULN?","url":null,"context":"CTEP"},{"name":"CRF Text 12","type":"Alternate Question Text","description":"Is the INR and aPTT less than or equal to 1.5 times the ULN?","url":null,"context":"CTEP"},{"name":"CRF Text 11","type":"Alternate Question Text","description":"Is the patient's international normalized ratio of prothrombin time (INR) and prothrombin time (PT) <= 1.5 x ULN for the lab within 28 days before randomization?","url":null,"context":"CTEP"},{"name":"CRF Text 13","type":"Alternate Question Text","description":"Is the patient's PT/INR less than 1.5 x ULN within 14 days prior to randomization?","url":null,"context":"CTEP"},{"name":"CRF Text 14","type":"Alternate Question Text","description":"Is the patient's PT/INR less than or equal to 1.5 x ULN within 14 days prior to randomization?","url":null,"context":"CTEP"},{"name":"CRF Text15","type":"Alternate Question Text","description":"Is this patient's International Normalized Ratio (INR) or Prothrombin Time (PT) less than or equal to 1.5 x institutional ULN?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Is the patient's PT/INR less than or equal to 1.5 x ULN within 14 days prior to study entry?","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Is the patient's international normalized ratio of prothrombin time (INR) and prothrombin time (PT) less than or equal to 1.5 x ULN for the lab within 28 days before randomization?","url":null,"context":"NRG"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8B6A7F53-486A-0AD5-E040-BB89AD433968","latestVersionIndicator":"Yes","beginDate":"2010-07-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-15","modifiedBy":"TSESU","dateModified":"2023-03-21","changeDescription":"Replaced VD Assessments Ind-3b 2958018v1 with VD ID#3506036 - Yes No Not Applicable Indicator - dbw","administrativeNotes":"7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"}}